Aragen Life Sciences Pvt. Ltd.

Aragen Life Sciences Pvt. Ltd. is a biotechnology firm dedicated to providing comprehensive research and development services that support pharmaceutical and biotech companies in drug discovery and development efforts. Founded in 2001, Aragen Life Sciences Pvt.

Ltd. operates from its headquarters in Hyderabad, India, focusing on drug discovery and development solutions. CEO Manni Kantipudi leads the company, which has engaged in a total of 4 deals. The latest funding was a SECONDARY BUYOUT on January 13, 2025, where Quadria Capital Investment Management invested USD 100 mn, bringing the total amount raised to USD 100 mn.

Aragen Life Sciences specializes in high-quality R&D services tailored for pharmaceutical and biotechnology sectors. Their offerings encompass drug discovery, development, and optimization services, addressing the needs of large pharmaceutical firms, biotech startups, and research institutions worldwide. Through a robust B2B model, Aragen Life Sciences provides contract research tailored to the complexities of drug development, leveraging advanced drug screening technologies and comprehensive preclinical assessments to facilitate efficient market entry for new therapeutics. In 2024, Aragen Life Sciences reported a revenue of USD 200.

24 mn, with an EBITDA of USD 53. 46 mn, generated mainly through partnerships with pharmaceutical and biotechnology companies for research services. The recent acquisition by Quadria Capital Investment Management will enable Aragen Life Sciences to enhance its infrastructure and expand its outsourcing services, particularly targeting innovators in the United States and Europe. The company is poised for growth in these regions, anticipating increased demand for their comprehensive R&D services.

Future initiatives include launching new product lines tailored to emerging market needs, with developments expected to roll out following the latest funding injection.